Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

FDA Grants Orphan Drug Designation to Rhenium (186Re) Obisbemeda for Leptomeningeal Metastases in Lung Cancer

March 12th 2025

The FDA granted orphan drug designation to rhenium (186Re) obisbemeda for the treatment of leptomeningeal metastases from lung cancer.

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

March 11th 2025

MT-8421, a novel engineered toxin body targeting CTLA-4, was not associated with grade 4 or 5 toxicities in patients with select advanced solid tumors.

Dr Salani on Novel Trial Designs and Therapies in Gynecologic Malignancies

March 11th 2025

Ritu Salani, MD, MBA, discusses considerations in clinical trial design and the evolving role of HER2-targeted ADCs in gynecologic malignancies.

Dr Garrido-Laguna on the Safety of Daraxonrasib in KRAS G12X–Mutated PDAC

March 11th 2025

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses the safety profile of daraxonrasib in patients with KRAS-mutated pancreatic ductal adenocarcinoma

SAR443216 Engages HER2 With Manageable Toxicity in Advanced HER2+ Solid Tumors

March 11th 2025

The feasibility and safety of treatment with SAR443216 support the further investigation of this agent in patients with advanced HER2-positive tumors.

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer

March 10th 2025

ALISCA-Breast1 is investigating alisertib plus endocrine therapy in HR-positive, HER2-negative recurrent or metastatic breast cancer.

Inavolisib Expands the PIK3CA-Mutated Metastatic HR+ Breast Cancer Treatment Paradigm: With Virginia Kaklamani, MD, DSc

March 10th 2025

Virginia Kaklamani, MD, DSc, discusses the mechanism of action of inavolisib and the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm.

China’s NMPA Approves Sacituzumab Tirumotecan for Pretreated EGFR+ Advanced NSCLC

March 10th 2025

The Chinese NMPA has approved sacituzumab tirumotecan for EGFR-mutant advanced NSCLC following progression on an EGFR TKI and chemotherapy.

China’s NMPA Accepts MAA for Foritinib in ALK+ Advanced NSCLC

March 10th 2025

China’s NMPA has accepted an MAA seeking the approval of foritinib for ALK-positive advanced non–small cell lung cancer.

Atirmociclib Plus Letrozole Demonstrates Preliminary Efficacy and Safety in HR+/HER2-Negative Metastatic Breast Cancer

March 9th 2025

Preliminary data showed atirmociclib plus letrozole yielded antitumor activity in HR-positive/HER2-negative metastatic breast cancer.

Patritumab Deruxtecan Demonstrates Meaningful Activity in HR+/HER2– Advanced Breast Cancer

March 8th 2025

Patritumab deruxtecan elicited responses with acceptable safety in hormone receptor–positive, HER2-negative advanced breast cancer.

Dr Tolaney on Considerations for Adjuvant CDK4/6 Inhibitors in HR+/HER2-Negative Breast Cancer

March 8th 2025

Sara M. Tolaney, MD, MPH, discusses considerations for the use of adjuvant CDK4/6 inhibitors in HR-positive, HER2-negative breast cancer.

Dr Jagsi on Factors for RT Omission After Breast-Conserving Surgery in Early Breast Cancer

March 7th 2025

Reshma Jagsi, MD, Dphil, discusses factors that could influence the omission of radiation therapy following breast-conserving surgery in early-stage breast cancer.

Dr Borgen on the Need for Improved Risk Stratification in Early-Stage Breast Cancer

March 7th 2025

Patrick I. Borgen, MD, discusses the need for improved risk stratification in early-stage breast cancer.

Imulnestrant Plus Abemaciclib Extends PFS Over SOC in ER+/HER2– Advanced Breast Cancer

March 7th 2025

Imlunestrant generated PFS benefit with or without abemaciclib for select patients with ER-positive, HER2-negative advanced breast cancer.

Ribociclib Efficacy Is Maintained With Dose Reductions in HR+/HER2-Negative Early Breast Cancer

March 7th 2025

A post hoc analysis of the NATALEE trial suggests that ribociclib dose reduction preserves iDFS in hormone receptor+/HER2-negative early breast cancer.

FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD

March 6th 2025

Dr Tap discusses the significance of this approval, key efficacy and safety data from the phase 3 MOTION trial, and the important role that multidisciplinary collaboration will play in integrating this therapy into clinical practice.

Versamune HPV–Based Immunotherapy Combo Demonstrates Benefit in Advanced HPV-Associated Cancers

March 6th 2025

Versamune HPV plus PDS01ADC and bintrafusp alfa demonstrated clinical benefit in locally advanced or metastatic HPV-associated cancers.

Immunotherapy Continues to Redefine Treatment Considerations in Advanced/Recurrent Endometrial Cancer

March 6th 2025

Matthew Wagar, MD, discusses treatment considerations for advanced/recurrent endometrial cancer.

Data Compilation Highlights Potential of SON-1010 to Enhance Therapeutic Efficacy in Solid Tumors

March 5th 2025

SON-1010 is being investigated for its potential to improve outcomes in solid tumors.